AstraZeneca

Q1 2024 Results

Conference call and webcast for investors and analysts

25 April 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the ability of the Group and Fusion to complete the transactions contemplated by the arrangement agreement with Fusion, including the parties' ability to satisfy the conditions set forth in the arrangement agreement with Fusion; the ability of the Group and Amolyt Pharma to complete the transactions contemplated by the acquisition agreement with Amolyt Pharma, including the parties' ability to satisfy the conditions set forth in the acquisition agreement with Amolyt Pharma; the Group's statements about the expected timetable for completing the acquisitions of Fusion and Amolyt Pharma; the Group's and Fusion's beliefs and expectations and statements about the benefits sought to be achieved in the Group's pending acquisition of Fusion; the Group's and Amolyt Pharma's beliefs and expectations and statements about the benefits sought to be achieved in the Group's proposed acquisition of Amolyt Pharma; the potential effects of the acquisition of Fusion on both the Group and Fusion and of the acquisition of Amolyt Pharma on both the Group and Amolyt Pharma; the possibility of any termination of the arrangement agreement with Fusion or of the acquisition agreement with Amolyt Pharma; the expected benefits and success of "FPI-2265" (Ac225-PSMA I&T) and any combination product or eneboparatide ("AZP-3601") and any combination product; the possibility that any milestone related to any contingent value right may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realized; the effects of disruption from the transactions contemplated by the acquisition agreement with Amolyt Pharma and the impact of the announcement and pendency of the transactions on Amolyt Pharma's business; the effects of disruption from the transactions contemplated by the arrangement agreement with Fusion and the impact of the announcement and pendency of the transactions on Fusion's business; the risk that shareholder litigation in connection with the offer or the acquisition may result in significant costs of defense, indemnification and liability; the risk of failure or delay in delivery of pipeline or launch of new medicines the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast. There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable or at all or that "FPI-2265" (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable or at all or that eneboparatide ("AZP-3601") will receive the necessary regulatory approvals or prove to be commercially successful if approved.

Q1 2024 Results

Conference call agenda

CEO Opening Remarks	**Pascal Soriot** Chief Executive Officer	
Financial Results	**Aradhana Sarin** Chief Financial Officer	
Oncology	**Dave Fredrickson** EVP, Oncology Business	**Susan Galbraith** EVP, Oncology R&D
BioPharmaceuticals	**Ruud Dobber** EVP, BioPharmaceuticals Business	**Sharon Barr** EVP, BioPharmaceuticals R&D
Rare Disease	**Marc Dunoyer** Chief Executive Officer, Alexion	
CEO Closing Remarks, Q&A	**Pascal Soriot** Chief Executive Officer	



Appendix: Glossary.

CEO Opening Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER



Strong delivery in Q1 2024

Total Revenue growth

fueled by global Product Sales



Core EPS growth

despite substantial decrease in Other Operating Income[1]



2024 dividend: 7% increase to $3.10

All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals. 1. $241 million dollar gain in the first quarter of 2023 following the divestment of Pulmicort Flexhaler in the US.
Appendix: Glossary.

Growth across therapy areas and geographies





Double-digit growth across therapy areas

Strong Emerging Markets performance, +26%

All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals.

Appendix: Glossary.

Q1 2024 pipeline events unlock significant growth potential

Unprecedented Phase III results

Phase III ADRIATIC trial

- *Imfinzi* potentially first IO therapy in LS-SCLC

Phase III LAURA trial

- Reinforcing *Tagrisso* as backbone TKI, expanding in early-stage *EGFR*m NSCLC

2024 ASCO ANNUAL MEETING | Phase III ADRIATIC and LAURA trials selected for plenary

Transformative new approvals

***Tagrisso* + CTx**	***Enhertu***	***Ultomiris***
1L *EGFR*m NSCLC	Tumour agnostic	NMOSD

Continued investment in recent launches

WAINUA™ Truqap™ Voydeya® AIRSUPRA™

All growth rates at CER. Due to rounding, the sum of a number or dollar values and percentages may not agree to totals. Collaboration partners: Ionis (*Wainua*).
Appendix: Glossary.

Financial Results

Aradhana Sarin
CHIEF FINANCIAL OFFICER



Q1 2024 – Reported profit and loss



	Q1 2024 $m	CER change %	% Total Revenue
- Product Sales	*12,177*	*18*	*96*
- Alliance Revenue	*457*	*59*	*4*
- Collaboration Revenue	*45*	*66*	*-*
Total Revenue	**12,679**	**19**	**100**
Product Sales Gross Margin	81.8%	-	
Total operating expense[1]	(7,413)	10	58
- R&D expense	(2,783)	7	22
- SG&A expense	(4,495)	12	35
Other operating income and expense	67	(83)	1
Operating profit	3,115	31	25
Tax rate	22%		
Reported EPS	**$1.41**	**30**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Absolute values at actual exchange rates; changes at CER. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Q1 2024 – Core profit and loss



	Q1 2024 $m	CER change %	% Total Revenue
- Product Sales	*12,177*	*18*	*96*
- Alliance Revenue	*457*	*59*	*4*
- Collaboration Revenue	*45*	*66*	*-*
Total Revenue	**12,679**	**19**	**100**
Product Sales Gross Margin	82.0%	-1pp	
Total operating expense[1]	(6,246)	15	49
- R&D expense	(2,698)	18	21
- SG&A expense	(3,413)	13	27
Other operating income and expense	65	(80)	1
Operating profit	4,310	15	34
Tax rate	21%		
Core EPS	**$2.06**	**13**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Absolute values at actual exchange rates; changes at CER. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
1. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Net debt and FY guidance

Reiterating FY 2024 guidance

Net debt bridge



FY 2024 guidance reiterated (CER)

Total Revenue

- Low double-digit to low teens percentage increase

Core EPS

- Low double-digit to low teens percentage increase

Net debt/Adjusted EBITDA 1.9x

Anticipated FX impact: low single-digit adverse impact on Total Revenue and mid single-digit impact on Core EPS[3]

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1.Comprises disposal of intangible assets, movement in profit participation liability, purchase of intangible assets, payment of contingent consideration on business combinations, purchase and disposal of non-current asset investments, payment of Acerta Pharma share purchase liability and acquisitions of subsidiaries, net of cash acquired. The Company uses Debt issuance to finance new Business Development opportunities 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $78m (FY 2023: $114m). AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook stable. S&P Global Ratings: short-term rating A-1, long-term rating A, outlook stable. 3. If foreign exchange rates for April to December were to remain at the average rates seen in March 2024. Appendix: Glossary.

Oncology

Dave Fredrickson
ONCOLOGY BUSINESS

Susan Galbraith
ONCOLOGY R&D



Oncology – Q1 2024

Total Revenue +26% with strong double-digit growth across all regions

Oncology

Q1 2024 $5.1bn, +26%



Q1 2024: key dynamics

- ***Tagrisso*** +15%, continued ADAURA and FLAURA demand, strong FLAURA2 awareness and early uptake in target patient segments
- ***Lynparza* PS** +11%, continued PARPi leadership
- ***Imfinzi*** +33%, achieved TOPAZ-1 (BTC) peak penetration in US, EU; JP repricing effective from February 1st
- ***Imjudo*** +70%, HIMALAYA (HCC) acceleration, durable POSEIDON (NSCLC) demand
- ***Calquence*** +35%, sustained BTKi leadership in 1L CLL
- ***Enhertu*** +79%, NPS growth in HER2+ (DB03), one-time EU pricing benefit, strong initial mBC uptake in Emerging Markets
- ***Truqap*** n/m, rapid adoption in core biomarker-altered population

---

- New indications: US (*Tagrisso* FLAURA2, *Enhertu* DPT02), JP (*Truqap* CAPItello-291)
- ASCO 2024 Plenaries: *Imfinzi* ADRIATIC, *Tagrisso* LAURA

All growth rates at CER.
Collaboration partners: Daiichi Sankyo (*Enhertu*), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology – R&D highlights

Fusion Pharmaceuticals acquisition expands next-gen Radioconjugate capabilities



30-50% of patients receive conventional radiotherapy[1]

Clinical-stage portfolio, combination potential with next-gen IO and DDR

Accelerates AstraZeneca's Radioconjugate research and manufacturing to commercial build

FPI-2265 in Prostate cancer

PSMA-Actinium RC with potential post-Pluvicto and Pluvicto-naïve

Maximum percent PSA change from baseline during the treatment period (weeks 0-28) by prior Lu treatment[2]



- PSA50 achieved in 43% of Lu-treated participants
- PSA50 achieved in 54% of Lu-naïve participants
- No discontinuations from Xerostomia

Multi-blockbuster opportunity in mCRPC with FPI-2265

1. KANTAR data, US 2025 estimates (across lung, head and neck, prostate, bladder, endometrial, ovarian, colon, rectal and gastric cancers) 2. TATCIST data presented at AACR 2024.
Fusion Pharmaceuticals acquisition remains subject to customary closing conditions; all clinical development plans mentioned herein subject to deal closure.
Appendix: Glossary.

BioPharmaceuticals

Ruud Dobber
BIOPHARMACEUTICALS BUSINESS

Sharon Barr
BIOPHARMACEUTICALS R&D



BioPharmaceuticals – Q1 2024

Total Revenue $5.2bn, +16% – demand growth, accelerating new launch momentum

CVRM

Q1 2024 $3.1bn, +23%



Q1 dynamics

- ***Farxiga*** +45%, demand growth outpacing SGLT2i
- ***Lokelma*** +19%, K+ Binder leadership in US
- **roxadustat** +28%, demand growth

R&I

Q1 2024 $1.9bn, +17%



Q1 dynamics

- ***Fasenra*** +6%, continued IL-5 class leadership
- ***Breztri*** +54%, global market share gains
- ***Tezspire*** >2x, strong global launch demand

AIRSUPRA™

- **>18k unique prescribers[1]**
- **65k TRx in 1Q24[2]**

WAINUA™ (eplontersen) 45 mg injection for subcutaneous use

- **Strong initial ATTRv-PN launch uptake**

Beyfortus

- **90% effective in preventing infant hospitalisation[3]**

All growth rates at CER.

1. IQVIA Xponent unique prescribers data, week ending 29 March 2. IQVIA NPA Data Monthly Ending 24 March. 3. Moline, Tannis, Toepfer et. al. Centres for Disease Control and Prevention, "Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024." March 2024. Collaboration partners: Amgen (*Tezspire*); Sanofi (*Beyfortus*).
Appendix: Glossary.

BioPharmaceuticals – R&D highlights

Exploratory endpoints support confidence in upcoming ATTR-CM opportunity



Phase III NEURO-TTRansform

Cardiomyopathic exploratory endpoints[1]



Exploratory data supports potential efficacy in ATTR-CM

CARDIO-TTRansform largest and only Phase III trial to incorporate cardiovascular mortality endpoints

Primary endpoint: composite of CV mortality and recurrent CV events

Secondary endpoint: change in 6MWT and KCCQ scores, rate of CV events, CV and all-cause mortality

Anticipate CARDIO-TTRansform trial readout 2025+

Collaboration partners: Ionis (*Wainua*).
Appendix: Glossary.

Rare Disease

Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION



Rare Disease – Q1 2024

Total Revenue +16% in Q1 2024 driven by neurology

Rare Disease

Q1 2024 $2.1bn, +16%



Q1 2024: key dynamics

Sustainable, durable growth of C5 Franchise

- ***Ultomiris*** +34%, driven by demand growth in neurology indications (gMG, NMOSD)
- ***Soliris*** (8%), continued conversion to *Ultomiris*, partly offset by growth in Emerging Markets

Strensiq +21% and ***Koselugo*** +82%, driven by continued global demand and order timing in certain Emerging Markets

- New indications: US (*Ultomiris* NMOSD, *Voydeya* PNH-EVH), EU (*Voydeya* PNH-EVH)

All growth rates at CER.
1. Includes *Kanuma* and *Koselugo*.
Collaboration partners: Merck & Co., Inc. (*Koselugo*).
Appendix: Glossary.

Rare Disease – R&D

Blockbuster opportunity with proposed Amolyt Pharma acquisition



eneboparatide | Phase IIa hypoparathyroidism



Clinical priorities:

- Normalising serum calcium levels
- Decreasing urinary calcium excretion
- Preserving bone mineral density

Anticipated Phase III CALYPSO data in 2025

Potential best-in-class therapy with differentiated mechanism of action

Strong strategic fit, furthering commitment to rare endocrinology

Large unmet need:

US:	EU5:	JP:
106k	105k	42k

Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure.
Appendix: Glossary.

CEO Closing Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER



Increasing momentum of high-value pipeline

Significant pipeline catalysts over the remainder of 2024

DESTINY-Breast06 *Enhertu*	2L HER2-low breast cancer	H1 2024
CAPItello-290 *Truqap*	Triple Negative Breast Cancer	H1 2024
CAPItello-281 *Truqap*	PTEN deficient mHSPC	H2 2024
TROPION-Breast02 Dato-DXd	Triple Negative Breast Cancer	H2 2024
WAYPOINT *Tezspire*	Chronic Rhinosinusitis with Nasal Polyps	H2 2024

Phase III trial initiations since FY2023

TROPION-Lung10 *Nonsq PDL1-high* | Dato-DXd ± rilvegostomig	**TROPION-Lung14**[1] *1L EGFRm NSCLC* | Dato-DXd ± *Tagrisso*
CLARITY-Gastric01 *2L+ Gastric* | AZD0901	**BalanceD-HF** *HF with renal imp* | balcinrenone / dapagliflozin FDC
ICAN *IgAN* | *Ultomiris*	**BaxDuo-Arctic** *CKD with HTN* | baxdrostat / dapagliflozin FDC
THARROS *COPD* | *Breztri*	**CHESTNUT** *HPP* | efzimfotase alfa

Pipeline enhanced with recent BD

Fusion Pharmaceuticals Inc. · AMOLYT PHARMA · ICOSAVAX · cellectis EDITING LIFE · GRACELL

1. First Subject In (FSI) anticipated in May 2024, trial posted on clinicaltrials.gov. Fusion Pharmaceuticals and Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure.
Appendix: Glossary.

Q&A Session

Pascal Soriot
EXECUTIVE DIRECTOR &
CHIEF EXECUTIVE OFFICER

Aradhana Sarin
EXECUTIVE DIRECTOR &
CHIEF FINANCIAL OFFICER

Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION

Susan Galbraith
EXECUTIVE VICE PRESIDENT,
ONCOLOGY R&D

Dave Fredrickson
EXECUTIVE VICE PRESIDENT,
ONCOLOGY BUSINESS

Sharon Barr
EXECUTIVE VICE PRESIDENT,
BIOPHARMACEUTICALS R&D

Ruud Dobber
EXECUTIVE VICE PRESIDENT,
BIOPHARMACEUTICALS
BUSINESS

Iskra Reic
EXECUTIVE VICE PRESIDENT,
VACCINES AND IMMUNE
THERAPIES

Leon Wang
EXECUTIVE VICE PRESIDENT,
INTERNATIONAL

Appendix & Glossary

- Glossary
- ESG – summary of sustainability progress
- Oncology tumour maps
- Emerging Markets performance
- Key medicines performance by therapy area



Glossary – abbreviations

1L	=	First-line or Front-line
2L	=	Second-line
6MWT	=	6-minute walk test
ADsCa	=	Albumin-adjusted serum calcium
ASCO	=	American society of clinical oncology
ATTR-CM	=	Transthyretin amyloid cardiomyopathy
ATTR-PN	=	Transthyretin amyloid polyneuropathy
BTC	=	Biliary tract cancer
BTKi	=	Bruton's tyrosine kinase
C5	=	Complement component 5
Capex	=	Capital expenditure
CER	=	Constant exchange rates
CFO	=	Cash flow from operations
CKD	=	Chronic kidney disease
CLL	=	Chronic lymphocytic leukemia
CLDN18.2	=	Claudin 18 isoform 2
cm	=	Centimeter
COPD	=	Chronic obstructive pulmonary disease
CTx	=	Chemotherapy
CV	=	Cardiovascular
CVRM	=	Cardiovascular, renal and metabolism
DDR	=	DNA damage response
EBITDA	=	Earnings before interest, tax, depreciation and amortisation
*EGFR*m	=	Epidermal growth factor receptor mutation
EPS	=	Earnings per share
ERoW	=	Established rest of world
EU	=	Europe
FDC	=	Fixed dose combination
FX	=	Foreign exchange
gMG	=	Generalised myasthenia gravis
HCC	=	Hepatocellular carcinoma
HF	=	Heart Failure
HLR	=	High-level results
hMPV/RSV	=	Human metapneumovirus/respiratory syncytial virus
HPP	=	Hypophosphatasia
HtN	=	Hypertension
IgAN	=	Immunoglobulin A Nephropathy
IL5	=	Interleukin 5
IO	=	Immuno-oncology
JP	=	Japan
K+	=	Potassium
KCCQ	=	Kansas City Cardiomyopathy Questionnaire
LS-SCLC	=	Limited stage small-cell lung cancer
LV	=	Left ventricular
mBC	=	Metastatic breast cancer
mg/dL	=	Miligrams per decilitre
mCRPC	=	Metastatic castration-resistant prostate cancer
mHSPC	=	Metastatic hormone sensitive prostate cancer
mL	=	Milliliter
n/m	=	Not material
NMOSD	=	Neuromyelitis optica spectrum disorder
Nonsq	=	Non-squamous
NSCLC	=	Non-small cell lung cancer
NT-proBNP	=	N-terminal pro-B-type natriuretic peptide
PARPi	=	Poly-ADP ribose polymerase inhibitor
PDL1	=	Programmed cell death ligand 1
PNH-EVH	=	Paroxysmal nocturnal hemoglobinuria with extravascular haemolysis
PSA	=	Prostate-specific antigen
PSA50	=	Prostate-specific antigen 50
PTEN	=	Phosphatase and TENsin homolog deleted on chromosome 10
R&I	=	Respiratory and immunology
RC	=	Radioconjugates
Renal imp	=	Renal impairment
SGLT2i	=	Sodium/glucose cotransporter 2 inhibitor
Stg. III u/r NSCLC	=	Stage III unresectable non-small cell lung cancer
TKI	=	Tyrosine kinase inhibitor
ULN	=	Upper limit of normal
V&I	=	Vaccines and immune therapies

2023 Sustainability highlights

Progress on our overall strategy includes:

15
public and private sector organisations convened by AstraZeneca CEO through the Sustainable Markets Initiative to accelerate transition to net-zero health systems

87%
of employee survey respondents say that they understand their contributions to our sustainability priorities

25/27
of sustainability targets in Sustainability Data Annex are **"on plan"**

Access to Healthcare

127,384
healthcare workers and others trained[1] (cumulative)
By 2025: 170,000

>66.4m
people reached through Access to Healthcare programmes (cumulative)[1]
By 2025: 50m

>13.6m
people reached through our patient assistance programmes (cumulative)

Environmental Protection

67.6%
reduction in Scope 1 and Scope 2 greenhouse gas emissions
By 2026: 98% from 2015 base year

19.5%
reduction in our water use
By 2025: 20% below 2015 baseline

13.2%
reduction in our waste
By 2025: 10% below 2015 baseline

Ethics and Transparency

50.1%
senior middle management roles held by women
By 2025: reach gender equality in management positions

11 countries
with supplier diversity programmes
By 2025: 10 new countries outside of the US

83%
of employee survey respondents feel we have a "speak up" culture

1. From our philanthropic programmes including; Healthy Heart Africa and Young Health Programme.

AstraZeneca in Lung Cancer

Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030

	resectable	unresectable		metastatic	
	Stg. I-III	Stg. I-II	Stg. III	1L	2L+
Est. epi (G7)	~200K	~30K	~70K	~350K	~290K
IO sensitive c.70%	*Imfinzi* **AEGEAN** volrustomig + CTx **NEOCOAST-2**	*Imfinzi* w/ SBRT **PACIFIC-4**	CRT → *Imfinzi* **PACIFIC** CRT + *Imfinzi* **PACIFIC-2** *Imfinzi* combos **PACIFIC-8, -9** improvements across PD-L1 spectrum	*Imfinzi* + *Imjudo* + CTx **POSEIDON** Dato-DXd + IO **TROPION-Lung08/TROPION-Lung07/AVANZAR** *Enhertu* + IO + CTx **DESTINY-Lung03** volrustomig + CTx **eVOLVE-Lung02** rilvegostomig (PD1/TIGIT) **ARTEMIDE-1**	*Imfinzi* + ceralasertib **LATIFY** Dato-DXd **TROPION-Lung01** AZD9592 (EGFR/cMET ADC) **EGRET** sabestomig (PD1/TIM3)
*EGFR*m c.16%	*Tagrisso* **ADAURA** *Tagrisso* **neoADAURA**		CRT → *Tagrisso* **LAURA**	*Tagrisso* **FLAURA** *Tagrisso* + CTx **FLAURA2**	savolitinib + *Tagrisso* **SAFFRON/SAVANNAH** AZD9592 (EGFR/cMET ADC) **EGRET**
Other tumour drivers c.12%			CRT → *Imfinzi* **PACIFIC**		Dato-DXd **TROPION-Lung01** **TROPION-Lung05**
*HER2*m c.2%				*Enhertu* **DESTINY-Lung04**	*Enhertu* **DESTINY-Lung02**

established SoC

Leading the future of lung cancer treatment

- Establishing *Tagrisso* as backbone TKI in *EGFR*m
- *Imfinzi* leading IO in unresectable
- Advancing best-in-class ADCs to replace systemic chemotherapy
- Delivering next-wave bispecifics to improve on PD1/PD-L1
- Developing novel combinations, including IO + ADCs
- Investing behind new technologies and platforms, including cell therapy and testing/screening

Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Compugen (rilvegostomig).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death



All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death



All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd).
Appendix: Glossary.

Oncology

Tagrisso

15% growth at CER to $1,595m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	406	400	406	356	444	408	409	360	488
ERoW	207	231	203	206	202	218	198	163	182
Europe	252	256	268	245	257	284	281	299	302
US	439	513	521	535	521	581	577	597	623

Lynparza

11% growth at CER to $705m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	121	120	117	130	137	142	131	133	167
ERoW	66	72	64	66	68	77	71	65	59
Europe	335	169	239	267	178	187	178	436	191
US	270	312	314	331	268	311	322	352	288

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partners: Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology

Imfinzi

33% growth at CER to $1,113m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	58	75	90	63	81	101	86	87	129
ERoW	101	104	99	97	129	201	207	213	170
Europe	125	142	135	142	162	171	203	207	232
US	315	374	413	437	491	540	570	570	582

Imjudo

70% growth at CER to $62m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	0	0	0	0	0	1	1	3	4
ERoW	0	0	0	0	4	22	14	12	11
Europe	0	0	0	0	1	5	5	5	8
US	0	0	0	13	32	36	40	38	39

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Oncology

Calquence

35% growth at CER to $718m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	7	8	12	17	18	24	28	29	39
ERoW	13	18	18	20	22	27	30	28	32
Europe	55	67	79	86	108	117	128	140	153
US	339	396	457	465	384	485	468	478	494

Enhertu

79% growth at CER to $461m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	9	17	25	29	38	69	72	74	112
ERoW	1	2	2	3	3	5	9	15	13
Europe	20	26	31	33	55	70	79	91	134
US	57	73	124	151	161	178	179	184	202

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partners: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

BioPharmaceuticals: Cardiovascular, Renal & Metabolism

Farxiga

45% growth at CER to $1,892m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	391	423	410	441	498	578	579	559	711
ERoW	99	98	84	72	138	136	105	73	152
Europe	318	309	329	342	393	456	506	525	553
US	193	275	279	323	296	339	366	451	475

Brilinta

1% decrease at CER to $323m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	69	78	76	64	82	79	64	61	88
ERoW	14	14	10	8	6	6	6	6	5
Europe	76	73	65	67	67	68	68	68	67
US	166	185	187	206	179	178	193	194	163

Lokelma

19% growth at CER to $114m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	3	2	9	6	11	13	13	13	21
ERoW	15	18	17	18	20	24	22	24	23
Europe	6	7	8	9	11	14	16	17	18
US	39	39	45	48	56	49	51	58	52

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Fasenra

6% growth at CER to $358m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	7	10	12	13	14	14	19	16	22
ERoW	37	36	35	35	35	36	35	36	33
Europe	75	78	77	76	88	89	86	93	93
US	189	230	229	257	201	267	249	275	210

Breztri

54% growth at CER to $219m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	22	21	28	21	38	43	42	38	70
ERoW	7	10	9	9	10	15	12	15	14
Europe	5	9	8	11	15	21	19	26	30
US	53	53	58	75	81	84	98	120	105

Tezspire

>2x growth at CER to $120m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	0	0	0	0	0	0	0	1	2
ERoW	0	0	0	2	4	8	10	14	14
Europe	0	0	0	2	7	11	11	17	27
US	3	13	26	37	43	62	74	83	77

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partners: Amgen (*Tezspire*).
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Symbicort

14% growth at CER to $769m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	167	139	169	133	229	177	195	153	253
ERoW	91	98	91	95	79	86	81	88	75
Europe	157	155	133	137	147	137	123	142	142
US	259	222	237	255	233	200	156	137	299

Pulmicort

5% growth at CER to $224m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	164	72	103	123	182	90	119	183	191
ERoW	13	12	12	12	9	11	11	12	8
Europe	18	17	14	19	20	16	13	19	20
US	22	15	16	12	10	7	5	5	5

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Rare Disease

Ultomiris

34% growth at CER to $859m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	24	6	4	4	13	17	17	24	32
ERoW	70	72	77	90	98	110	131	138	143
Europe	105	120	122	134	159	152	184	173	202
US	220	236	315	365	381	434	445	490	482

Soliris

8% decrease at CER to $739m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	71	63	84	83	115	99	124	86	125
ERoW	107	174	104	91	88	86	74	68	61
Europe	221	216	190	179	183	184	163	140	142
US	591	574	523	491	448	445	420	421	411

Strensiq

21% growth at CER to $313m in Q1 2024



	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
EM	9	9	8	10	15	9	5	11	21
ERoW	19	19	19	19	21	22	21	22	22
Europe	19	21	18	19	21	21	22	25	24
US	161	193	192	224	205	248	237	247	246

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.